aod9604 mechanism of action fat loss Obesity Pharmacotherapy: Current Perspectives and Future Directions AOD 9604 Peptide for Weight

The earlier 12-week Phase 2a trial had shown encouraging results (2.6 kg vs 0.8 kg for placebo), but the larger, longer, better-powered trial reversed that finding

both oral supplements and injections have proven to be effective (56 -59)

If you do lose some weight while receiving lipotropic injections, this is likely more due to other factors in your weight loss program like exercise and diet than to the shots alone

AOD-9604 Peptide Vial Research AOD-9604, also known as the Anti-Obesity Drug-9604, is a modified synthetic peptide fragment of natural human growth hormone

GHK-Cu Timeline & What to Monitor Topical clinical trials of GHK-Cu generally measured endpoints at 8-12 weeks